J&J no longer co-promoting Capoten
Executive Summary
Bristol-Myers Squibb and Johnson & Johnson's McNeil Pharmaceutical unit agree to discontinue, effective June 21, the co-promotion arrangement covering the ACE inhibitor product. McNeil's 450-rep sales force had been promoting Capoten to primary care physicians since January 1988. Bristol-Myers, which acquired Squibb in 1989, explained that the merger "now enables us to use our own greatly expanded sales force to sell Capoten in the U.S."